Elios Therapeutics announced positive top-line results from the prospective, randomized, double-blind, placebo-controlled phase IIb clinical trial evaluating its lead immuno-oncology candidate, TLPLDC (tumor lysate, particle-loaded, dendritic cell) vaccine, in patients with stage 3 and 4 resected melanoma.
More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.
